Read by QxMD icon Read

Expert Review of Pharmacoeconomics & Outcomes Research

Jonathan D Campbell, Zoltán Kaló
No abstract text is available yet for this article.
September 14, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Wiesława Dominika Wranik, Christopher Skedgel, Min Hu
INTRODUCTION: Health Technologies Assessment requires that evidence about clinical, economic, social, and organizational aspects be considered and weighted in the selection of drugs for reimbursement. We investigate how evidence is balanced by committee members in Canada, where neither explicit weighing schemes nor thresholds are provided. METHODS: Thirty-six past and present members of cancer drug appraisal committees participated in an online stated preferences experiment...
September 13, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Joseph S Aleshaki, Leah A Cardwell, Mikél E Muse, Steven R Feldman
The emergence of immune-modulating drugs such as biologics has altered the treatment landscape for psoriasis. However, their use presents high financial costs to patients and healthcare systems. Patient demographic and socioeconomic status may influence adherence to biologic medications and usage of healthcare resources. Areas covered: We performed a systematic literature review to summarize the available evidence pertaining to biologic medication adherence and resource use. PubMed was searched using the terms 'psoriasis and adherence' and 'psoriasis biologics resource use...
September 10, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
M Reaney, L Stassek, M Martin, K McCarrier, A Slagle, A Shields, C J Gwaltney
BACKGROUND: This paper outlines the creation of an intuitive, personalized evaluation framework for Patient-Reported Outcomes, using the EQ-5D visual analog scale (VAS) as an illustration. METHODS: A draft framework asked patients to divide and label the EQ-5D-VAS into different levels or categories of health. Comprehension of the framework and patient-defined health level labels, and how they map onto the EQ-5D-VAS, were tested through in-person, semi-structured interviews with individuals self-reporting cardiovascular disease...
September 6, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Antonio Naranjo, Soledad Ojeda-Bruno, Aida Saavedra, Amparo Molina, Miguel Negrín
INTRODUCTION: Fracture Liaison Service (FLS) model for secondary prevention of fractures has demonstrated its cost-effectiveness using decision models. We analyze the impact of a FLS on pharmaceutical expenditures for osteoporosis (OP) in real-world circumstances. METHODS: Expenditures on OP medications from January 2011 to January 2017 were compiled. Pharmaceutical expenditures in the southern area of Gran Canaria were used as a control group to measure the impact of implementing an FLS in the northern area...
September 6, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Vladica M Veličković, Ursula Rochau, Annette Conrads-Frank, Frank Kee, Stefan Blankenberg, Uwe Siebert
Despite the emphasis on the clinical importance of cardiac troponin assays (cTn), there are insufficient cost-effectiveness comparisons of various troponin test protocols for the diagnosis of myocardial infarction (MI). Therefore, the purpose of the review was to identify and systematically assess published economic evaluations using decision-analytic models for diagnostic testing strategies based on cTn and to make recommendations for the development of future models. Areas covered: MEDLINE, Science Direct, Cochrane Database, CRD Database, and gray literature were screened for full economic evaluation studies with relevant clinical outcomes over a defined time horizon addressing a population with suspected MI and comparison of different diagnostic test strategies...
September 6, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Antoni Sicras-Mainar, Javier Rejas-Gutiérrez, María Pérez-Paramo, Luis Sánchez-Alvarez, Ruth Navarro-Artieda, Josep Darbà
BACKGROUND: Discrepancies are seen between arguments in favor of and against prescribing generic versus brand-name drugs. OBJECTIVE: To provide real-world evidence on treatment persistence, economic and clinical outcomes of pregabalin, generic versus brand-name (Lyrica®, Pfizer), routinely used to treat neuropathic pain (NP) or generalized-anxiety-disorder (GAD). METHODS: Electronic-medical-records from subjects' first starting treatment with pregabalin between January-2015 and June-2016 were retrospectively analyzed...
September 5, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Sara Ramzan, Peter Timmins, Syed Shahzad Hasan, Zaheer-Ud-Din Babar
There is a growing need to evaluate the factors contributing to the increase in health expenditures, as well as the cost of medicines used in the treatment of Type 2 diabetes mellitus (T2DM) in the economically developed countries. Areas covered: A systematic searching of studies describing the direct cost of T2DM and medicine cost of treating T2DM. The quality of the studies found eligible for this study were assessed using a methodological quality appraisal tool. Nine studies were included in this review...
September 4, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ewa Orlewska, Renata Stępień, Katarzyna Orlewska
Somatostatin analogues (SSAs) are the largest contributor to the direct medical cost of acromegaly management worldwide. The aim of this review was to identify and report available evidence on the cost-effectiveness of SSAs in the treatment of acromegaly. Areas covered: A literature search on relevant papers published up to April 2018 was performed. A total of 22 eligible studies (10 full-text articles and 12 conference abstracts) conducted in 14 countries were included in the analysis. In majority of studies, modelling technique was the principal research method...
September 3, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Hosein Ameri, Mahmood Yousefi, Mehdi Yaseri, Azin Nahvijou, Mohammad Arab, Ali Akbari Sari
INTRODUCTION: Economic evaluation of healthcare interventions usually needs accurate data on utility and health-related quality of life scores. The aim of this study is to map QLQ-C30 scale score onto EQ-5D-5L and SF-6D utility values in CRC patients. METHODS: Three standard instruments (EQ-5D-5L, SF-SD and QLQ-C30) were completed by 252 patients with CRC who were referred to three cancer centers in Tehran between May and September 2017. Moreover, OLS, Tobit, and CLAD models were used to predict EQ-5D-5L and SF-6D values...
September 1, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurélie Millier, Olivia Wu
Introduction Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding of the value of DOACs relative to vitamin K antagonists (VKAs). Areas covered A systematic literature review was conducted on the available real-world evidence (RWE) of three DOACs (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients with non-valvular atrial fibrillation (NVAF)...
August 31, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
András Inotai, Huong Thanh Nguyen, Budi Hidayat, Talgat Nurgozhin, Pham Huy Tuan Kiet, Jonathan D Campbell, Bertalan Németh, Nikos Maniadakis, Diana Brixner, Kalman Wijaya, Zoltán Kaló
Multiple Criteria Decision Analysis (MCDA) is increasingly used in health care mainly because it moves decision-making from ad hoc to an evidence-based and comprehensive process. Developing countries with more restricted financial and human research capacities, however, should consider their own methods of MCDA development and implementation. Areas covered: An MCDA framework to improve procurement decisions of off-patent pharmaceuticals was developed for developing countries and adapted to Indonesia, Kazakhstan and Vietnam during three policy workshops...
August 24, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ana-Maria Ionescu, Abela Mpobela Agnarson, Chrispin Kambili, Laurent Metz, Jonathan Kfoury, Steven Wang, Abeda Williams, Vikram Singh, Adrian Thomas
BACKGROUND: Drug-resistant tuberculosis (DR-TB) continues to be a major public health challenge with suboptimal treatment outcomes including well-documented treatment-related toxicities. We compared the cost-effectiveness of bedaquiline (BDQ) containing regimens with injectable containing regimens (short-course regimen [SCR] and long-course regiman [LCR]) in India, Russia, and South Africa. METHODS: The analysis evaluated the direct costs of DR-TB treatment which included drugs, hospitalization, injectable-related adverse event costs, and other costs...
August 23, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Pedro Laires, Karen Kurtyka, Edward A Witt, Ying Qiu, Shengsheng Yu, Kristy Iglay
BACKGROUND: Sulfonylureas (SUs) can help manage T2DM, but they often have side effects. The objective of this study was to identify factors impacting physicians' decisions to discontinue (DC) or down-titrate (DT) SU therapy. RESEARCH DESIGN AND METHODS: Physicians recruited from the AllGlobal physician panel were asked to rate level of concern regarding potential reasons for DC or DT on a 7-point Likert scale (1=not concerned, 7=extremely concerned). Physicians were also asked to provide information regarding treatment decisions from one DC patient, one DT patient, and 2 current SU users' medical records...
August 22, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ines Potočnjak, Robert Likić, Vesna Degoricija, Eric Nham, Björn Wettermark
BACKGROUND: The consumption of psychotropic drugs (PD) is increasing worldwide with a significant variation between countries. Croatia and Sweden have similar health and pharmaceutical systems; however, Sweden is a high-income country with developed medical care, registries, and prescribing guidelines. We sought to compare the utilization of PD between Croatia and Sweden to identify areas for improvement in rational use of drugs. METHODS: This was a cross-sectional study using national databases to assess utilization of PD (ATC N05, N06) in Croatia and Sweden in 2014 and 2015...
August 13, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Maarten J IJzerman, A M Sofie Berghuis, Johann S de Bono, Leon W M M Terstappen
Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management...
August 7, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Nick Kontodimopoulos, Eleni Stamatopoulou, Aikaterini Brinia, Michael A Talias, Lara N Ferreira
BACKGROUND: Systematic discrepancies have been shown in utility values derived from different instruments. This study compares utilities from the condition-specific AQL-5D and the generic EQ-5D-3L and SF-6D in an asthmatic population with heterogeneous health-related quality of life (HRQoL), disease severity, and control status. METHODS: A consecutive sample of 104 patients diagnosed with asthma completed a survey containing the Greek versions of SF-36, EQ-5D-3L, and AQLQ(s)...
August 3, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Axel Leporowski, Brian Godman, Amanj Kurdi, Sean MacBride-Stewart, Margaret Ryan, Simon Hurding, Renata Crm Do Nascimento, Marion Bennie, Alec Morton
BACKGROUND: Prescribing of lipid-lowering agents (LLAs) has increased worldwide including in Scotland with increasing prevalence of coronary heart disease, and higher dose statins have been advocated in recent years. There have also been initiatives to encourage prescribing of generic versus patented statins to save costs without compromising care. There is a need to document these initiatives and outcomes to provide future direction. METHOD: Assessment of utilization (items dispensed) and expenditure of key LLAs (mainly statins) between 2001 and 2015 in Scotland alongside initiatives...
August 3, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Ali Hassan Gillani, Muhammad Majid Aziz, Imran Masood, Anum Saqib, Caijun Yang, Jie Chang, Mohamed Izham Mohamed Ibrahim, Yu Fang
BACKGROUND: Diabetes mellitus (DM) has a very high prevalence and poses a huge financial encumbrance on patients. This study aimed to evaluate the cost of diabetes care among patients with type 2 diabetes in private clinics of southern Punjab, Pakistan. RESEARCH DESIGN AND METHODS: This was a descriptive, cross-sectional, prevalence-based, cost-of-illness (COI) study conducted in six private clinics of southern Punjab from July to September 2016, using a pretested questionnaire...
August 1, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Samuel N Frempong, Andrew J Sutton, Clare Davenport, Pelham Barton
To evaluate the potential economic value and likely impact of a hypothetical rapid test in its early stages of development requires the use of models. The model structure and the type of model (dynamic/static) to employ are key considerations. The aim of the review was to explore the literature on typhoid economic evaluations and to explore the types of models that have been previously adopted in this setting for test-treat evaluations and to capture data on model inputs that may be useful for a de novo model...
July 30, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"